# 信達生物與輝瑞簽訂合作協議，共同開發腫瘤藥物。

*biotech · news · 2026-05-29 · CNBC*

## Key points

- 信達生物將從輝瑞獲得6.5億美元的前期付款。
- 該協議促成12款早期癌症藥物的共同開發與共同商業化。
- 信達將保留這些癌症藥物在大中華區的權利，並與輝瑞共享其他地區的利潤。
- 信達有資格獲得高達98.5億美元的里程碑付款，使該協議總額達到105億美元。
- 信達將通過此合作夥伴關係，從獲批產品銷售中獲得兩位數百分比的版稅收入。

Shares of Innovent Biologics rose 10% after the company entered into a deal with pharmaceutical giant Pfizer to develop oncology medicines. The partnership, which includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates, will involve the research and development of 12 breakthrough early-stage and de novo cancer medicines, the company said in a filing. Innovent will develop four global programs with Pfizer, sharing costs. In addition, the Hong Kong-listed biotech company will co-commercialize with Pfizer in the U.S. and Europe and share profits, though Innovent will retain rights to these programs in the Greater China market. Innovent will receive an upfront payment of $650 million and is eligible to receive up to $9.85 billion in development, regulatory and commercial milestone payments, which would bring the total value of the deal to up to $10.5 billion. "Additionally, Innovent will receive up to double-digit royalties on sales of each product if approved," the company said, adding that closing of the transaction is subjected to regulatory approvals. Partnerships between biotech firms and pharmaceutical companies are in focus amid concerns over the rise of oncology-related diseases globally. "Large pharmaceutical companies, in particular, utilized licensing as a surgical tool to address near-term pipeline gaps ahead of the "2026–2030 patent cliff," according to a report by Gibson Dunn. Innovent shares were up 6.41% to HK$79.65.

**Companies:** Pfizer, Innovent Biologics
**Countries:** China, United States, Hong Kong

[Read the full story on CNBC](https://www.cnbc.com/2026/05/29/innovent-shares-rise-10percent-after-pact-with-pfizer-of-up-to-10point5-billion.html)

---

Canonical: https://newsio.io/zh-TW/n/5f75f4aa-08bd-4bd0-bc4b-03f359d5efd5/6-598-5
Summarized by Newsio from CNBC. https://newsio.io/how-it-works